永安药业（002365）8月25日主力资金净流出1769.18万元

Core Points - Yong'an Pharmaceutical (002365) reported a closing price of 19.97 yuan as of August 25, 2025, with a slight increase of 0.3% [1] - The company experienced a significant net outflow of main funds amounting to 17.69 million yuan, representing 5.61% of the total transaction amount [1] - The latest quarterly report indicated a total revenue of 171 million yuan, a year-on-year decrease of 12.96%, and a net profit attributable to shareholders of 4.37 million yuan, down 115.23% year-on-year [1] Financial Performance - Total revenue for the first quarter of 2025 was 171 million yuan, reflecting a decrease of 12.96% compared to the previous year [1] - Net profit attributable to shareholders was 4.37 million yuan, showing a significant decline of 115.23% year-on-year [1] - The company's non-recurring net profit was 6.67 million yuan, down 133.39% year-on-year [1] - Current ratio stood at 5.289, quick ratio at 4.876, and debt-to-asset ratio at 10.45% [1] Company Overview - Yong'an Pharmaceutical Co., Ltd. was established in 2001 and is located in a county-level administrative region directly under the province [2] - The company primarily engages in the manufacturing of chemical raw materials and chemical products [2] - Registered capital is 294.68 million yuan, with paid-in capital of 82.57 million yuan [1] - The legal representative of the company is Chen Yong [1] Investment and Intellectual Property - Yong'an Pharmaceutical has made investments in 9 external companies and participated in 20 bidding projects [2] - The company holds 3 trademark registrations and 38 patent registrations [2] - Additionally, it possesses 277 administrative licenses [2]